Introduction {#tca12762-sec-0005}
============

Treatment with EGFR‐tyrosine kinase inhibitors (TKIs) is the standard of care for advanced non‐small cell lung cancer (NSCLC) patients with an *EGFR* sensitizing mutation; however, acquired resistance is inevitable, occurring within 10--12 months of treatment.[1](#tca12762-bib-0001){ref-type="ref"}, [2](#tca12762-bib-0002){ref-type="ref"} Various resistance mechanisms have been identified. Understanding such mechanisms is critical to guide further treatment for patients with EGFR‐TKI resistant NSCLC.[3](#tca12762-bib-0003){ref-type="ref"} Among the EGFR‐TKI resistance mechanisms, T790M mutations, which substitute threonine (T) with methionine (M) at position 790 of exon 20 of the *EGFR* gene are the most common, accounting for more than 50%.[4](#tca12762-bib-0004){ref-type="ref"} Other resistance mechanisms include amplification of the *MET* gene, *PIK3CA* and *BRAF* mutations, epithelial‐to‐mesenchymal transition, and small cell lung cancer transformation.[3](#tca12762-bib-0003){ref-type="ref"}, [4](#tca12762-bib-0004){ref-type="ref"}, [5](#tca12762-bib-0005){ref-type="ref"} Thus, re‐biopsy of sufficient tissue for molecular analysis is necessary to identify the resistance type and guide further treatment decisions after EGFR‐TKI treatment failure.[6](#tca12762-bib-0006){ref-type="ref"}

With the development of third generation EGFR‐TKIs, re‐biopsy is even more important in order to identify T790M mutations. Several studies have reported high success rates of re‐biopsy, ranging from 75% to 97%.[6](#tca12762-bib-0006){ref-type="ref"}, [7](#tca12762-bib-0007){ref-type="ref"}, [8](#tca12762-bib-0008){ref-type="ref"}, [9](#tca12762-bib-0009){ref-type="ref"}, [10](#tca12762-bib-0010){ref-type="ref"}, [11](#tca12762-bib-0011){ref-type="ref"} However, re‐biopsy is still challenging in real practice because of several hurdles, including tissue availability, procedural feasibility, and limited accessibility to new anti‐cancer drugs, which differ in different countries. As limited data is available on the feasibility of re‐biopsy and its clinical impact in real‐world clinical practice, the aim of this study was to assess successful re‐biopsy rates and the factors influencing re‐biopsy in Korean real world clinical practice.[6](#tca12762-bib-0006){ref-type="ref"}, [10](#tca12762-bib-0010){ref-type="ref"}, [12](#tca12762-bib-0012){ref-type="ref"}, [13](#tca12762-bib-0013){ref-type="ref"} In addition, we evaluated *EGFR* mutation status and clinical factors associated with an increased frequency of T790M mutations.

Methods {#tca12762-sec-0006}
=======

Patients and materials {#tca12762-sec-0007}
----------------------

This retrospective, observational study included all patients diagnosed with NSCLC who experienced disease progression after EGFR‐TKI therapy at the Chonnam National University Hwasun Hospital between January 2014 and December 2016. Disease progression was confirmed by chest computed tomography (CT) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progression was defined not only as progression after initial response or durable (\> 6 months) stable disease after EGFR‐TKIs, but also intrinsic resistance to EGFR‐TKIs. Patients who discontinued EGFR‐TKIs before disease progression or whose RECIST responses were not confirmed were excluded. Re‐biopsy procedures included surgery, bronchoscopy, endobronchial ultrasonography (EBUS)‐guided transbronchial needle aspiration (TBNA), percutaneous core needle biopsy (PCNB), excisional biopsy, fine needle aspiration (FNA), lumbar puncture, pericardiocentesis, and thoracentesis.

All data were gathered in accordance with the amended Declaration of Helsinki, following approval from an independent hospital institutional review board (IRB approval no.: CNUHH‐2017‐108). The need for written informed consent was waived because of the retrospective design of the study.

*EGFR* mutation test {#tca12762-sec-0008}
--------------------

We used the PNA Clamp Mutation Detection Kit (Panagene Inc., Daejeon, Korea) to detect *EGFR* gene mutations using real‐time PCR from DNA acquired from formalin fixed paraffin‐embedded tumor tissue samples or liquid‐based cytology samples. DNA was isolated using a Gene All Tissue DNA Purification Kit (General Biosystems, Seoul, Korea) according to manufacturer protocol. All reactions were performed in 20 μL volumes using template DNA, primer, PNA probe set, and fluorescence PCR master mix. All reagents were included in the kit. Real‐time PCR reaction of PNA‐mediated clamping PCR was performed using a CFX 96 (BioRad Laboratories Inc., Hercules, CA, USA). PCR cycling conditions were set at a five minute hold at 94°C for 40 cycles, at 94°C for 30 seconds, 70°C for 20 seconds, 63°C for 30 seconds, and 72°C for 30 seconds. The pooled sensitivity and specificity of the PNA clamp methods were 93% and 100%, respectively.[14](#tca12762-bib-0014){ref-type="ref"}, [15](#tca12762-bib-0015){ref-type="ref"}

Statistical analysis {#tca12762-sec-0009}
--------------------

All data were expressed as medians and interquartile ranges or as numbers (%) in the text and tables. Intergroup comparisons were performed using the Mann--Whitney *U* test for continuous variables, and Pearson\'s χ^2^ or Fisher\'s exact tests for categorical variables. Multivariate analysis was performed to determine the feasibility of re‐biopsy using a binary logistic regression. All analyses were performed using SPSS version 19.0 (IBM Corp., Armonk, NY, USA). A *P* value \< 0.05 indicated statistical significance.

Results {#tca12762-sec-0010}
=======

Patients {#tca12762-sec-0011}
--------

A total of 230 NSCLC patients who experienced progression after EGFR‐TKI treatment were reviewed (Table [1](#tca12762-tbl-0001){ref-type="table"}). The median age was 68.0 years (59.8--74.0) with women comprising 47.4% of the total. Adenocarcinoma (90.4%) was the most common histology. The EGFR‐TKIs used were gefitinib (47.0%), erlotinib (48.7%), and afatinib (4.3%). The median duration of treatment was 247 (82--459) days. The initial biopsy specimen was used to detect *EGFR* mutation in 211 patients. Of the 230 patients included, 66 (28.7%) had exon 19 deletions, 62 (27.0%) had L858R mutations, and 68 (29.6%) were wild type. In addition, 9 (3.9%) patients had uncommon mutations, such as G719X, S768I, or exon 20 insertion; 2 (0.9%) patients had de novo T790M mutations; and although tests were conducted, the results were not available in 4 (1.7%) cases.

###### 

Baseline characteristics of NSCLC patients who experienced EGFR‐TKI failure (*n* = 230)

  Characteristics                                          Value
  ------------------------------------------------- -------------------
  Age (years)                                        68.0 (59.8--74.0)
  Gender, male                                          109 (47.4%)
  Smoking                                           
  Current smoker                                        57 (24.8%)
  Ex‐smoker                                             50 (21.7%)
  Never smoker                                          123 (53.5%)
  ECOG performance status                           
  0                                                      4 (1.7%)
  1                                                     167 (72.6%)
  2                                                     43 (18.7%)
  3                                                      11 (4.8%)
  4                                                      5 (2.2%)
  Histology                                         
  ADC                                                   208 (90.4%)
  SQC                                                    15 (6.5%)
  NSCLC                                                  5 (2.2%)
  LCNEC                                                  1 (0.4%)
  SCLC + ADC                                             1 (0.4%)
  EGFR‐TKI                                          
  Gefitinib                                             108 (47.0%)
  Erlotinib                                             112 (48.7%)
  Afatinib                                               10 (4.3%)
  Treatment line                                    
  1st line                                              125 (54.3%)
  2nd line                                              72 (31.3%)
  3rd line                                              23 (10.0%)
  \> 4th line                                            10 (4.4%)
  Duration of EGFR‐TKI therapy, days                   247 (82--459)
  *EGFR* mutation status at diagnosis (*n* = 211)   
  Exon 19 deletion                                      66 (28.7%)
  Exon 21 L858R                                         62 (27.0%)
  Wild type                                             68 (29.6%)
  Uncommon mutations                                     9 (3.9%)
  De novo T790M mutation                                 2 (0.9%)
  Invalid                                                4 (1.7%)

Values are presented as number (%) or median with interquartile range.

ADC, adenocarcinoma; ECOG, Eastern Cooperative Oncology Group; LCNEC, large cell neuroendocrine carcinoma; NSCLC, non‐small cell lung cancer; SCLC, small cell lung cancer; SQC, squamous cell carcinoma; TKI, tyrosine kinase inhibitor.

Characteristics of re‐biopsy {#tca12762-sec-0012}
----------------------------

Re‐biopsy was performed on 105 (45.7%) patients, while 125 (53.4%) did not undergo re‐biopsy. Reasons for not performing re‐biopsy included patients receiving salvage systemic chemotherapy without re‐biopsy (*n* = 69), best supportive care (*n* = 52), refusal to perform re‐biopsy (*n* = 2), and patients lost to follow‐up (*n* = 2). Of the 105 patients who underwent re‐biopsy, 94 (89.5%) were pathologically diagnosed with malignancy from 59 histological and 35 cytological samples (Fig [1](#tca12762-fig-0001){ref-type="fig"}). The most common sampling method was intrathoracic, which included video‐assisted thoracoscopic surgery (*n* = 3), bronchoscopy with EBUS‐TBNA (*n* = 25), CT‐guided PCNB (*n* = 17), pericardiocentesis (*n* = 2), and thoracentesis (*n* = 30) (Table [2](#tca12762-tbl-0002){ref-type="table"}). The primary tumor was more frequently used for the initial biopsy than the re‐biopsy (59.6% vs. 30.5%; *P* \< 0.001). Metastatic lesions were more frequently used for re‐biopsy than initial biopsy (53.3% vs. 13.0%; *P* \< 0.001). Most specimens used for the initial biopsy were tissue samples (84.4%). In contrast, the proportion of cytology sample specimens used was significantly higher in re‐biopsy than initial biopsy (40.0% vs. 15.3%; *P* \< 0.001).

![Flow chart of subject enrollment.](TCA-9-856-g002){#tca12762-fig-0001}

###### 

Comparison between initial biopsy and re‐biopsy

  Variables                      Initial biopsy (*n* = 230)   Re‐biopsy (*n* = 105)     *P*
  ----------------------------- ---------------------------- ----------------------- ----------
  Site of biopsy                                                                      \< 0.001
  Primary tumor                         137 (59.6%)                32 (30.5%)        
  Regional lymph node                    63 (27.4%)                17 (16.2%)        
  Metastasis                             30 (13.0%)                56 (53.3%)        
  Method of biopsy                                                                    \<0.001
  Tissue                                195 (84.8%)                63 (60.0%)        
  Surgery                                43 (18.7%)                 10 (9.5%)          0.371
  Lung                                       35                         3            
  Brain                                      4                          3            
  Femur                                      3                          1            
  Spine                                      1                          3            
  Small biopsy                          152 (66.1%)                53 (50.5%)        
  Bronchoscopy + EBUS                       111                        25            
  CT‐guided PCNB                             26                        17            
  SCL biopsy                                 13                         6            
  Liver biopsy                               1                          2            
  Adrenal biopsy                             1                          2            
  Gastroscopy                                0                          1            
  Cytology                               35 (15.2%)                42 (40.0%)        
  Bronchial brushing cytology                12                         0            
  Thoracentesis                              20                        30            
  Lumbar puncture                            0                          6            
  FNA from lymph node                        3                          3            
  Pericardiocentesis                         0                          2            
  Paracentesis                               0                          1            

Values are presented as number (%).

CT, computed tomography; EBUS, endobronchial ultrasound; FNA, fine needle aspiration; PCNB, percutaneous needle biopsy; SCL, supraclavicular lymph node; VATS, video‐assisted thoracoscopic surgery.

We compared the clinical characteristics of patients who underwent re‐biopsy with those who did not. In univariate analysis, patients who underwent re‐biopsy were younger, had good performance status, more sensitizing mutations, better previous responses (complete or partial response), and a longer treatment duration than those who did not. In multivariate analysis, the frequency of re‐biopsies performed was significantly higher in younger patients (65 vs. 69 years; *P* = 0.002) and in patients with a previous response to EGFR‐TKIs (*P* \< 0.001) (Table [3](#tca12762-tbl-0003){ref-type="table"}).

###### 

Comparison between the characteristics of patients who underwent re‐biopsy and those who did not

  Characteristics                                  No re‐biopsy (*n* = 125)   Re‐biopsy (*n* = 105)   *P* (univariate)       Multivariate       
  ----------------------------------------------- -------------------------- ----------------------- ------------------ ----------------------- -----------
  Age, years                                          69.0 (63.0--75.0)         65.0 (54.0--73.0)          0.001         0.950 (0.922--0.980)      0.001
  Gender, male                                            53 (42.4%)               56 (53.3%)              0.235                                
  Smoking history                                                                                          0.666                                
  Current smoker                                          34 (27.2%)               23 (21.9%)                                                   
  Ex‐smoker                                               26 (20.8%)               24 (22.9%)                                                   
  Never smoker                                            65 (52.0%)               58 (55.2%)                                                   
  ECOG performance status                                                                                  0.004         4.830 (0.956--24.391)     0.057
  0--2                                                   111 (88.8%)               103 (98.1%)                                                  
  3--4                                                    14 (11.2%)                2 (1.9%)                                                    
  Histology                                                                                                0.108                                
  ADC                                                    110 (88.0%)               99 (94.3%)                                                   
  SQC                                                     12 (11.4%)                3 (2.9%)                                                    
  NSCLC                                                    2 (1.9%)                 3 (2.9%)                                                    
  EGFR‐TKI                                                                                                 0.006                                   0.106
  Gefitinib                                               69 (55.2%)               39 (37.1%)                                                   
  Erotinib                                                54 (43.2%)               58 (55.2%)                                                   
  Afatinib                                                 2 (1.6%)                 8 (7.6%)                                                    
  *EGFR* mutation status                                                                                   0.001                                   0.265
  19 deletion and L858R                                   58 (44.9%)               70 (66.0%)                                                   
  Others[†](#tca12762-note-0005){ref-type="fn"}           67 (55.1%)               35 (34.0%)                                                   
  Treatment line                                                                                           0.058                                
  1st line                                                60 (48.0%)               65 (61.9%)                                                   
  2nd line                                                39 (31.2%)               33 (31.3%)                                                   
  3rd line                                                18 (14.4%)                5 (4.8%)                                                    
  ≥ 4th line                                               8 (6.4%)                 2 (2.0%)                                                    
  Best response                                                                                          \< 0.0001       7.210 (3.203--16.229)   \< 0.0001
  Complete response                                        4 (3.2%)                 4 (3.8%)                                                    
  Partial response                                        48 (38.4%)               70 (66.7%)                                                   
  Stable disease                                          27 (21.6%)               21 (20.0%)                                                   
  Progressive disease                                     46 (36.8%)                10 (9.5%)                                                   
  Duration of EGFR‐TKIs, days                           131 (55--353)            348 (172--508)          \< 0.0001                                 0.222

"Others" includes wild‐type, G719X, uncommon mutations, de novo T790M, and invalid cases.

Values are presented as number (%) or median with interquartile range.

ADC, adenocarcinoma; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; NSCLC, non‐small cell lung cancer; SQC, squamous cell carcinoma; TKI, tyrosine kinase inhibitor.

Eleven cases (7 cytology, 4 tissue) were not pathologically confirmed. The seven cytology specimens consisted of three cases of cerebrospinal fluid and four of pleural fluid. Bronchoscopy was used to obtain the four tissue samples in which malignant cells were not acquired. The pathological success rate was higher in tissue (93.7%) than cytology (83.3%) specimens.

Safety {#tca12762-sec-0013}
------

The complication rate was 8.6% (9/105). Pneumothorax was the most common complication, occurring in seven patients: five who underwent PCNB, and two who underwent bronchoscopy. Of the seven patients, two required tube thoracostomy. Hemoperitoneum occurred in one patient who underwent US‐guided adrenal biopsy and one death occurred as a result of respiratory failure two days after bronchoscopy.

*EGFR* mutation analysis of re‐biopsied samples {#tca12762-sec-0014}
-----------------------------------------------

Of 94 patients, 75 (71.4%) were tested for *EGFR* mutation (Fig [2](#tca12762-fig-0002){ref-type="fig"}, Table [4](#tca12762-tbl-0004){ref-type="table"}). Nineteen patients were not tested because of the unavailability of effective drugs, such as third generation EGFR‐TKIs (42.1%); the detection of other resistance mechanisms (10.5%); a deteriorated condition (10.5%); enrollment in other clinical trials (15.8%); and a lack of durable response to EGFR‐TKIs (21.1%). When re‐biopsied, 30 (52.6%) of the 57 patients initially detected with sensitizing mutations only harbored their initial mutation, while 19 (33.3%) were positive for T790M mutation. The initial *EGFR* mutation disappeared in 8 (14.1%) patients. Among the 10 patients with wild type, T790M mutations were newly detected in 2 (20.0%) and sensitizing mutations in 2 (20.0%).

![*EGFR* mutation analysis of re‐biopsied samples.](TCA-9-856-g001){#tca12762-fig-0002}

###### 

Changes in *EGFR* mutation status between initial diagnosis and re‐biopsy specimens (*n* = 75)

  *EGFR* mutation status                                Value
  -------------------------------------------------- ------------
  Sensitizing mutation at diagnosis (*n* = 57)       
  Sensitizing mutation → only sensitizing mutation    30 (40.0%)
  Sensitizing mutation → positive T790M               19 (25.3%)
  Sensitizing mutation → wild type                    8 (10.7%)
  Wild type at diagnosis (*n* = 10)                  
  Wild type → wild type                                6 (8.0%)
  Wild type → positive T790M                           2 (2.7%)
  Wild type → sensitizing mutation                     2 (2.7%)
  Other types at diagnosis (*n* = 8)                 
  G719X → 19 deletion and T790M                        1 (1.3%)
  G719X → G719X                                        2 (2.7%)
  G719X and T790M → 19 deletion                        1 (1.3%)
  Ins. 3 duplication → wild type                       1 (1.3%)
  Invalid → wild type                                  1 (1.3%)
  Unknown → L858R                                      1 (1.3%)
  Unknown → wild type                                  1 (1.3%)

Values are presented as number (%).

The prevalence of T790M mutations was not statistically different to sensitive mutations (38.2% in 19 deletion vs. 26.1% in L858R), specimen type (29.4% in cytology vs. 35.0% in tissue samples), pleural effusion (23.1% in pleural effusion vs. 36.4% in other specimens), or cancer burden (27.9% in intrathoracic disease vs. 50.0% in extra‐thoracic metastasis) (Table [5](#tca12762-tbl-0005){ref-type="table"}).

###### 

Prevalence of T790M mutations according to clinical characteristics

  Characteristics                    T790M (%)    *P*
  --------------------------------- ----------- -------
  *EGFR* mutation at diagnosis                   0.569
  Exon 19 deletion (*n* = 34)        13 (38.2)  
  L858R mutation (*n* = 23)          6 (26.1)   
  Specimen type of re‐biopsy                     0.845
  Tissue (*n* = 40)                  14 (35.0)  
  All cytology (*n* = 17)            5 (29.4)   
  Pleural effusion (*n* = 13)        3 (23.1)   
  Site of re‐biopsy                              0.845
  Intrathoracic lesion (*n* = 43)    12 (27.9)  
  Extrathoracic lesion (*n* = 14)    7 (50.0)   
  EGFR‐TKIs                                      0.107
  Gefitinib (*n* = 21)               8 (38.1)   
  Erlotinib (*n* = 29)               11(38.0)   
  Afatinib (*n* = 7)                  0 (0.0)   

Values are presented as number (%).

Discussion {#tca12762-sec-0015}
==========

We conducted a retrospective study on the feasibility of re‐biopsy in 230 NSCLC patients in whom EGFR‐TKI treatment had failed in Korean real‐world clinical practice. Re‐biopsy was performed in 105 (45.7%) patients to decide subsequent treatment or to improve symptoms. With a 100% technical success rate and an 89.5% pathological success rate (93.7% in tissue and 83.3% in cytology samples), re‐biopsy was feasible and *EGFR* mutation analysis was performed in 71.4% of all patients who had undergone invasive procedures. The complication rate was 8.6% and mortality was 0.95%. T790M mutations were reported in 33.3% of cases, unlike previous reports that detected such mutations in approximately 50% of patients.[7](#tca12762-bib-0007){ref-type="ref"}, [10](#tca12762-bib-0010){ref-type="ref"}, [16](#tca12762-bib-0016){ref-type="ref"}, [17](#tca12762-bib-0017){ref-type="ref"}, [18](#tca12762-bib-0018){ref-type="ref"} We were unable to determine the specific characteristics related to T790M prevalence.

With the development of new treatments for NSCLC, including third‐generation EGFR‐TKIs and immune checkpoint inhibitors, the importance of re‐biopsy has increased.[19](#tca12762-bib-0019){ref-type="ref"}, [20](#tca12762-bib-0020){ref-type="ref"}, [21](#tca12762-bib-0021){ref-type="ref"}, [22](#tca12762-bib-0022){ref-type="ref"}, [23](#tca12762-bib-0023){ref-type="ref"} However, re‐biopsy is still challenging in real world clinical practice because of its invasiveness and the different medical environments found in different countries. Recently, several reports reflecting the reality in different countries have been published.[8](#tca12762-bib-0008){ref-type="ref"}, [22](#tca12762-bib-0022){ref-type="ref"}, [24](#tca12762-bib-0024){ref-type="ref"}, [25](#tca12762-bib-0025){ref-type="ref"}, [26](#tca12762-bib-0026){ref-type="ref"} Most studies reported a high re‐biopsy success rate, ranging from 75% to 97%,[6](#tca12762-bib-0006){ref-type="ref"}, [7](#tca12762-bib-0007){ref-type="ref"}, [9](#tca12762-bib-0009){ref-type="ref"}, [11](#tca12762-bib-0011){ref-type="ref"} similar to the results of our study. The re‐biopsy complication rate is reported to be 1.3--5.8%,[10](#tca12762-bib-0010){ref-type="ref"}, [11](#tca12762-bib-0011){ref-type="ref"} which is similar to that of initial lung biopsy. In this study, the complication rate was 8.6%, with most cases developing pneumothorax that improved after conservative treatment, including a high oxygen supply. One death occurred as a result of respiratory failure two days after bronchoscopic re‐biopsy. In that patient, the right main bronchus was almost completely obstructed by the tumor mass and we believe that the patient progressed to respiratory failure because of the rapidly progressing cancer, not as a result of the procedure. This emphasizes the importance of candidate choice before performing an invasive procedure, such as as re‐biopsy, following EGFR‐TKI failure.

When the biopsy sites and procedures performed in this study were compared, the initial biopsy at diagnosis was more frequently performed on the primary tumor (59.6%), while re‐biopsy was more frequently performed on metastatic lesions (53.3%). We believe this is because there is greater access to the tumor site during the initial biopsy. Most samples for the initial biopsy came from tissue (84.8% vs. 15.2%), while a large proportion of the samples for re‐biopsy came from cytology (60.0% 40.0%). Bronchoscopy and/or EBUS are the main methods used for both initial biopsy and re‐biopsy at our institution. Thoracentesis for pleural effusion is frequently performed during re‐biopsy.

In our study, 11 cases were not pathologically confirmed and the pathological success rate was higher in tissue (93.7%) than cytology (83.3%) specimens. Cerebrospinal and pleural fluid may not yield a sufficient number of cancer cells, thus repeated puncture could increase diagnostic yield. In addition, all tissue specimens that were not pathologically confirmed were obtained by bronchoscopy. However, it may be difficult to determine a site for re‐biopsy by bronchoscopy because of secondary mucosal changes, such as necrosis or fibrosis after previous cancer therapy.

Although re‐biopsy is beneficial for treatment decision‐making it may be impossible to perform in some patients because of difficulty accessing the tumor site or poor performance status; many patients in our study could not undergo re‐biopsy for these reasons. In our study the patients who underwent re‐biopsy were younger and had a better response to previous EGFR‐TKIs. In these cases, it may be that the re‐biopsy was conducted when the patients were performing well, satisfied with previous *EGFR* targeted therapy, and had high expectations of further treatment.

T790M mutations are the most common acquired resistance mechanism, accounting for 50% to 63% of mutations.[4](#tca12762-bib-0004){ref-type="ref"}, [7](#tca12762-bib-0007){ref-type="ref"}, [10](#tca12762-bib-0010){ref-type="ref"}, [16](#tca12762-bib-0016){ref-type="ref"}, [17](#tca12762-bib-0017){ref-type="ref"}, [18](#tca12762-bib-0018){ref-type="ref"} In this study, using the PNA Clamp method, only 33.9% of patients with sensitizing mutations exhibited T790M mutations. The first explanation for the lower prevalence is our small study sample. Secondly, the PNA Clamp test is not highly sensitive to T790M mutations. Thirdly, T790M prevalence may be low in real world clinical practice, as a result of several confounding factors, including poor sample quality and DNA denaturation. Our results were similar to those of several retrospective studies conducted in Japan, which reported that the prevalence of T790M mutations is 33--34% in real world clinical practice.[3](#tca12762-bib-0003){ref-type="ref"}, [13](#tca12762-bib-0013){ref-type="ref"}

The prevalence of T790M mutations with exon 19 deletions in our study was higher than L858R mutations, although this result was not statistically significant (41.2% vs. 26.1%; *P* = 0.569). This result is consistent with the results of several previous studies.[10](#tca12762-bib-0010){ref-type="ref"}, [27](#tca12762-bib-0027){ref-type="ref"} Ke *et al*. reported a higher prevalence of T790M mutations with exon 19 deletions than L858R mutations. Such patients achieve greater survival periods because third generation EGFR‐TKIs targeting the T790M mutation can be administered.[25](#tca12762-bib-0025){ref-type="ref"}

First‐line EGFR‐TKI treatment is the standard of care for advanced NSCLC patients with an *EGFR* sensitizing mutation. However, EGFR‐TKIs could be used as second or third‐line treatments, even in patients with *EGFR* wild type, based on the results of the INTEREST study.[28](#tca12762-bib-0028){ref-type="ref"} We performed re‐biopsies in 10 patients harboring *EGFR* wild type because the initial detection method may not have been accurate in cases with small biopsy specimens. Tseng *et al*. reported that a significant portion of the response in *EGFR* wild‐type patients to erlotinib was related to limitations in detection methods, not only direct sequencing, but also sensitive mutant type‐specific methods.[29](#tca12762-bib-0029){ref-type="ref"} In our study, four cases of sensitizing mutation or T790M were newly found by re‐biopsy in patients harboring wild‐type *EGFR* at initial diagnosis. This result suggested that re‐biopsy may be considered even in *EGFR* wild type cases, particularly in patients who have shown a good response to EGFR‐TKIs. In addition, we identified several strange changes in *EGFR* status between the initial biopsy and re‐biopsy, such as alteration from wild‐type to T790M or from G719X/T790M to exon 19 deletions. These discrepancies seem to be related to the insufficient sensitivity of mutation testing or sample processing errors rather than representing new resistance mechanisms.

Recent advances in highly sensitive genotyping technologies have allowed for the development of novel plasma genotyping assays that are capable of noninvasively detecting targetable alterations in circulating tumor cells or plasma cell‐free DNA.[30](#tca12762-bib-0030){ref-type="ref"} Plasma genotyping allows oncologists to rapidly obtain information on tumor genotypes while avoiding the inherent risk and discomfort associated with tissue biopsy.[30](#tca12762-bib-0030){ref-type="ref"} Liquid biopsy has the advantage of identifying resistance mechanisms with only a blood sample, but despite its rapid development, which led to an explosion in the number of highly sensitive assay platforms available from both commercial and laboratory sources, its sensitivity remains lower than that of re‐biopsy.[31](#tca12762-bib-0031){ref-type="ref"} Thus, it is critical to confirm the mechanism of acquired resistance using tumor biopsy as liquid biopsy is limited and can produce false negative results.[30](#tca12762-bib-0030){ref-type="ref"}, [32](#tca12762-bib-0032){ref-type="ref"}

In conclusion, this retrospective study indicates that re‐biopsy is feasible in NSCLC patients who experience EGFR‐TKI treatment failure in Korean real world clinical practice, especially in younger patients and those with a previous response to *EGFR* targeted therapy. *EGFR* mutation analysis can be performed in most re‐biopsied patients, which is beneficial to help guide further therapeutic strategies. However, a large‐scale multi‐center study is needed to better understand lung cancer progression.
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